Parasites After Hematopoietic Stem Cell or Solid Organ Transplantation



Parasitic infections in the setting of transplantation, although uncommon, are being increasingly recognized. They may represent a significant threat for a successful outcome. Extensive human travel and immigration, and climatic changes are re-shaping the epidemiology of parasitic infections, allowing for their emergence in unexpected settings. Transplant physicians should get familiar with parasitic infections and promote adherence to preventive measures in transplant recipients. Parasitic diseases in the transplant recipient may result from recrudescence of dormant or unrecognized parasitic infections in the potential transplant recipient after starting immunosuppression, or from de novo acquisition either from transmission of an infected graft or infected blood products, or by naturally occurring infection. Thorough knowledge of clinical manifestations and diagnostic methods for parasitic disease allows for early diagnosis, implementation of preventive measures, or for adequate monitoring to detect reactivation and initiation of timely pre-emptive treatment.


Parasites Solid organ transplantation Hematopoietic stem cell transplantation Infection 



The authors would like to acknowledge Dr. Roberta Lattes, who was the first co-author of the previous versions of this chapter; Dr. Silvia A. Repetto for her helpful suggestions and review, and Mrs. Brenda Koliren for her assistance reviewing the English version of the manuscript.


  1. 1.
    Barsoum RS. Parasitic infections in transplant recipients. Nat Clin Pract Nephrol. 2006;2(9):490–503.CrossRefPubMedGoogle Scholar
  2. 2.
    WHO. Available at: Accessed 1 June 2015.
  3. 3.
    Bell A, Monaghan P, Page AP. Peptidyl-prolyl cis-trans isomerases (immunophilins) and their roles in parasite biochemistry, host-parasite interaction and antiparasitic drug action. Int J Parasitol. 2006;36(3):261–76.CrossRefPubMedGoogle Scholar
  4. 4.
    Rodriques Coura J, Castro S. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002;97:3–24.CrossRefPubMedGoogle Scholar
  5. 5.
    Kirchhoff L. American trypanosomiasis (Chagas’ disease). In: Gillespie S, Pearson RD, editors. Principles and practice of clinical parasitology. New York: Wiley; 2001. p. 335–53.CrossRefGoogle Scholar
  6. 6.
    Bern C. Chagas disease: natural history and diagnosis. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed 12 Apr 2015.Google Scholar
  7. 7.
    Haberland A, Saravia SG, Wallukat G, Ziebig R, Schimke I. Chronic Chagas disease: from basics to laboratory medicine. Clin Chem Lab Med. 2013;51(2):271–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Mitelman J, Descalzo A, Gimenez L, Pesce R, Romero Villanueva H. Consensus statement on Chagas-Mazza Disease. Argentine J Cardiol, North America, 79, Dec. 2011. Available at: Accessed 12 June 2015.
  9. 9.
    Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1:92–100.CrossRefPubMedGoogle Scholar
  10. 10.
    Sica RE, Gonzalez Cappa SM, Sanz OP, Mirkin G. Peripheral nervous system involvement in human and experimental chronic American trypanosomiasis. Bull Soc Pathol Exot. 1995;88(4):156–63.PubMedGoogle Scholar
  11. 11.
    Strout RG. A method for concentrating hemoflagellate. J Parasitol. 1962;48:100–1.CrossRefPubMedGoogle Scholar
  12. 12.
    Britto C, Cardoso A, Silveira C, Macedo V, Fernandes O. Polymerase chain reaction (PCR) as a laboratory tool for the evaluation of the parasitological cure in Chagas disease after specific treatment. Medicina. 1999;59:176–8.PubMedGoogle Scholar
  13. 13.
    Zulantay I, Apt W, Valencia C, Torres A, Saavedra M, Rodríguez J, et al. Detection of Trypanosoma cruzi in untreated chronic chagasic patients is improved by using three parasitological methods simultaneously. J Antimicrob Chemother. 2011;66(10):2224–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Brasil PE, De Castro L, Hasslocher-Moreno AM, Sangenis LH, Braga JU. ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect Dis. 2010;10:337.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Otani MM, Vinelli E, Kirchhoff LV, del Pozo A, Sands A, Vercauteren G, et al. WHO comparative evaluation of serologic assays for Chagas disease. Transfusion. 2009;49(6):1076–82.CrossRefPubMedGoogle Scholar
  16. 16.
    Gorlin J, Rossmann S, Robertson G, Stallone F, Hirschler N, Nguyen KA, et al. Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening. Transfusion. 2008;48:531–40.CrossRefPubMedGoogle Scholar
  17. 17.
    Guías para la atención al paciente infectado con Trypanosoma cruzi (Enfermedad de Chagas). Buenos Aires: Ministerio de Salud de la Nación, 2012. Accessed 12 Apr 2015 (Spanish).
  18. 18.
    Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370(20):1899–908.CrossRefPubMedGoogle Scholar
  19. 19.
    Araujo MS, Martins-Filho OA, Pereira ME, Brener Z. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas’ disease. J Antimicrob Chemother. 2000;45:819–24.CrossRefPubMedGoogle Scholar
  20. 20.
    Bern C. Antitrypanosomal therapy for chronic Chagas’ disease. N Engl J Med. 2011;364(26):2527–34.CrossRefPubMedGoogle Scholar
  21. 21.
    Bern C. Antitrypanosomal drug therapy for Chagas disease. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed 12 Apr 2015.Google Scholar
  22. 22.
    Keenan M, Chaplin JH. A new era for Chagas disease drug discovery? Prog Med Chem. 2015;54:185–230.CrossRefPubMedGoogle Scholar
  23. 23.
    Gallerano RH, Marr JJ, Sosa RR. Therapeutic efficacy of allopurinol in patients with chronic Chagas’ disease. Am J Trop Med Hyg. 1990;43:159–66.CrossRefPubMedGoogle Scholar
  24. 24.
    Perez-Mazliah DE, Alvarez MG, Cooley G, Lococo BE, Bertocchi G, Petti M, et al. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother. 2013;68(2):424–37.CrossRefPubMedGoogle Scholar
  25. 25.
    Muñoz-Saravia SG, Haberland A, Wallukat G, Schimke I. Chronic Chagas’ heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine. Heart Fail Rev. 2012;17(1):45–64.CrossRefPubMedGoogle Scholar
  26. 26.
    Centers for Disease Control and Prevention (CDC). Blood donor screening for Chagas disease—United States, 2006–2007. MMWR Morb Mortal Wkly Rep. 2007;56(7):141–3.Google Scholar
  27. 27.
    REAL DECRETO 1088/2005, de 16 de septiembre, por el que se establecen los requisitos técnicos y condiciones mínimas de la hemodonación y de los centros y servicios de transfusión. Accessed 14 Apr 2015 (Spanish).
  28. 28.
    Kitchen AD, Hewitt PE, Chiodini PL. The early implementation of Trypanosoma cruzi antibody screening of donors and donations within England: preempting a problem. Transfusion. 2012;52(9):1931–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Basile L, Jansa JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, et al. Working Group on Chagas Disease. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill. 2011;16(37). pii: 19968.Google Scholar
  30. 30.
    Alctlas JD, Barcan L, Nagel C, Lattes R, Riarte A. Organ transplantation and Chagas disease. JAMA. 2008;299(10):1134 (letter).Google Scholar
  31. 31.
    Chagas’ Disease Argentine Collaborative Transplant Consortium, Casadei D. Chagas’ disease and solid organ transplantation. Transplant Proc. 2010;42(9):3354–9.Google Scholar
  32. 32.
    Cura CI, Lattes R, Nagel C, Gimenez MJ, Blanes M, Calabuig E, et al. Early molecular diagnosis of acute Chagas disease after transplantation with organs from Trypanosoma cruzi-infected donors. Am J Transplant. 2013;13(12):3253–61.CrossRefPubMedGoogle Scholar
  33. 33.
    Riarte A, Luna R, Sabatiello R, Sinagra A, Schiavelli R, De Rissio A, et al. Chagas’ disease in patients with kidney transplants: 7 years experience, 1989–1996. Clin Infect Dis. 1999;29:561–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Kransdorf EP, Czer LS, Luthringer DJ, Patel JK, Montgomery SP, Velleca A, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant. 2013;13(12):3262–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Üders C, Caetano MA, Ianhez LE, Fonseca JA, Sabbaga E. Renal transplantation in patients with Chagas’ disease: a long term follow-up. Transplant Proc. 1992;24:1878–9.Google Scholar
  36. 36.
    Lattes R, Radisic M, Leon L, Rial M, Casadei D. Chagas disease in kidney transplantation: a single center experience. Transplantation. 2012;94(10S):555 (abstract).Google Scholar
  37. 37.
    Jardim E, Takayanagui OM. Chagasic meningoencephalitis with detection of Trypanosoma cruzi in the cerebrospinal fluid of an immunodepressed patient. J Trop Med Hyg. 1994;97(6):367–70.PubMedGoogle Scholar
  38. 38.
    Cicora F, Escurra V, Bibolini J, Petroni J, González I, Roberti J. Cerebral trypanosomiasis in a renal transplant recipient. Transpl Infect Dis. 2014;16(5):813–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Kocher C, Segerer S, Schleich A, Caduff R, Wyler LG, Müller V, et al. Skin lesions, malaise, and heart failure in a renal transplant recipient. Transpl Infect Dis. 2012;14(4):391–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Hemmige V, Tanowitz H, Sethi A. Trypanosoma cruzi infection: a review with emphasis on cutaneous manifestations. Int J Dermatol. 2012;51(5):501–8.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas’ disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994;127(1):151–62.CrossRefPubMedGoogle Scholar
  42. 42.
    Barcan L, Clara L, Valledor A, et al. Chagas disease in liver transplant recipients: no evidence of reactivation. Presented at the Sixth International Liver Transplantation Society Congress, Buenos Aires, Argentina, 21–23 June 2000. Abstract 85.Google Scholar
  43. 43.
    Squassi V, Nagel C, Riarte A, et al. Outcome of liver transplantation in patients with Chagas disease. Presented at the Sixth International Liver Transplantation Society Congress, Buenos Aires, Argentina, 21–23 June 2000. Abstract 84.Google Scholar
  44. 44.
    Jacob N, Maiolo E. Chagas y trasplante. Controversias. Presented at the 6th Congreso Argentino de Trasplante de Organos. Mar del Plata, Argentina, 28–30 November 2001. Abstract 43 (Spanish).Google Scholar
  45. 45.
    Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. Ann Thorac Surg. 2001;71:1833–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Diez M, Favaloro L, Bertolotti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas’ disease reactivation and treatment follow-up in heart transplantation. Am J Transplant. 2007;7:1633–40.CrossRefPubMedGoogle Scholar
  47. 47.
    Seguro LF, Braga FGM, Avila MS, et al. Profile of heart transplant recipients in a Brazilian center: comparison with international registry. J Heart Lung Transplant. 2014;33:S264.Google Scholar
  48. 48.
    Kapelusznik L, Varela D, Montgomery SP, et al. Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City. Clin Infect Dis. 2013;57(1), e7.CrossRefPubMedGoogle Scholar
  49. 49.
    Traina M, Sanchez D, Hernandez S, et al. Abstract 18171: Chagasic cardiomyopathy is associated with increased morbidity and mortality compared to nonischemic cardiomyopathy among Latin American immigrants living in Los Angeles. American Heart Association Scientific Sessions; 2013.Google Scholar
  50. 50.
    Godier-Furnemont AFG, Topkara VK, Mancini D. Management of Chagas cardiomyopathy patients following cardiac transplantation: implications from the Unos Database. J Heart Lung Transplant. 2015;34(4):S186–7.Google Scholar
  51. 51.
    Zingales B, Miles MA, Campbell DA, et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol. 2012;12(2):240–53.CrossRefPubMedGoogle Scholar
  52. 52.
    Schijman AG, Bisio M, Orellana L, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis. 2011;5(1), e931.PubMedCentralCrossRefPubMedGoogle Scholar
  53. 53.
    Bocchi EA, Bellotti G, Mocelin A, et al. Heart transplantation for chronic Chagas’ heart disease. Ann Thorac Surg. 1996;61:1727–33.CrossRefPubMedGoogle Scholar
  54. 54.
    Bestetti RB, Souza TR, Lima MP, et al. Effects of a mycophenolate mofetil based immunosuppressive regimen in Chagas’ heart transplant recipients. Transplantation. 2007;84(3):441–2.CrossRefPubMedGoogle Scholar
  55. 55.
    de Souza MM, Franco M, Almeida DR, Diniz RV, Mortara RA, da Silva S, Reis da Silva Patrício F. Comparative histopathology of endomyocardial biopsies inchagasic and non-chagasic heart transplant recipients. J Heart Lung Transplant. 2001;20(5):534–43.CrossRefPubMedGoogle Scholar
  56. 56.
    Schijman AG, Vigliano C, Burgos J, Favaloro R, Perrone S, Laguens R, et al. Early diagnosis of recurrence of Trypanosoma cruzi infection by polymerase chain reaction after heart transplantation of a chronic Chagas’ heart disease patient. J Heart Lung Transplant. 2000;19(11):1114–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Benvenuti LA, Roggério A, Coelho G, Fiorelli AI. Usefulness of qualitative polymerase chain reaction for Trypanosoma cruzi DNA in endomyocardial biopsy specimens of chagasic heart transplant patients. J Heart Lung Transplant. 2011;30(7):799–804.CrossRefPubMedGoogle Scholar
  58. 58.
    Campos SV, Strabelli TM, Amato Neto V, Silva CP, Bacal F, Bocchi EA, Stolf NA. Risk factors for Chagas’ disease reactivation after heart transplantation. J Heart Lung Transplant. 2008;27(6):597–602.CrossRefPubMedGoogle Scholar
  59. 59.
    Theodoropoulos TA, Bestetti RB. Risk factors for Trypanosoma cruzi infection reactivation in Chagas’ heart transplant recipients: do they exist? J Heart Lung Transplant. 2008;27(10):1186–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Stoppani A. The chemotherapy of Chagas disease. Medicina (B Aires). 1999;59:147–65 (Spanish).Google Scholar
  61. 61.
    Rodrigues Almeida D, Caravalho ACC, Branco JN, et al. Chagas’ disease reactivation after heart transplantation: efficacy of allopurinol treatment. J Heart Lung Transplant. 1996;15:988–92.Google Scholar
  62. 62.
    Tomimori-Yamashita J, Deps PD, Almeida DR, et al. Cutaneous manifestation of Chagas’ disease after heart transplantation: successful treatment with allopurinol. Br J Dermatol. 1997;137:626–30.CrossRefPubMedGoogle Scholar
  63. 63.
    Bacal F, Silva CP, Bocchi EA, Pires PV, Moreira LF, Issa VS, et al. Mycophenolate mofetil increased Chagas disease reactivation in heart transplanted patients: comparison between two different protocols. Am J Transplant. 2005;5(8):2017–21.CrossRefPubMedGoogle Scholar
  64. 64.
    Guiang KM, Cantey P, Montgomery SP, et al. Reactivation of Chagas disease in a bone marrow transplant patient: case report and review of screening and management. Transpl Infect Dis. 2013;15(6):E264–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Altclas J, Jaimovich G, Milovic V, et al. Chagas’ disease after bone marrow transplantation. Bone Marrow Transplant. 1996;18:447–8.PubMedGoogle Scholar
  66. 66.
    Dictar M, Sinagra A, Veron MT, et al. Recipients and donors of bone marrow transplant suffering from Chagas’ disease: management and pre-emptive therapy of parasitemia. Bone Marrow Transplant. 1998;21:391–3.CrossRefPubMedGoogle Scholar
  67. 67.
    Altclas J, Singara A, Jaimovich G, et al. Reactivation of chronic Chagas’ disease following allogeneic bone marrow transplantation and successful pre-emptive therapy with benznidazole. Transpl Infect Dis. 1999;1:135–7.CrossRefPubMedGoogle Scholar
  68. 68.
    Gea-Banacloche J, Masur H, Arns da Cunha C, et al.; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention. Regionally limited or rare infections: prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):489–94.Google Scholar
  69. 69.
    Altclas J, Sinagra A, Dictar M, et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant. 2005;36(2):123–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Angheben A, Giaconi E, Menconi M, et al. Reactivation of Chagas disease after a bone marrow transplant in Italy: first case report. Blood Transfus. 2012;10(4):542–4.PubMedCentralPubMedGoogle Scholar
  71. 71.
    Villalba R, Fornés G, Alvarez MA, et al. Acute disease in a recipient of bone marrow transplant in Spain: case report. Clin Infect Dis. 1992;14:594–5.CrossRefPubMedGoogle Scholar
  72. 72.
    Huprikar S, Bosserman E, Patel G, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011. Am J Transplant. 2013;13(9):2418–25.CrossRefPubMedGoogle Scholar
  73. 73.
    Cicora F, Escurra V, Silguero S, et al. Use of kidneys from Trypanosoma cruzi-infected donors in naive transplant recipients without prophylactic therapy: the experience in a high-risk area. Transplantation. 2014;97(1):e3–4.CrossRefPubMedGoogle Scholar
  74. 74.
    D’Albuquerque LA, Gonzalez AM, Filho HL, et al. Liver transplantation from deceased donors serologically positive for Chagas disease. Am J Transplant. 2007;7(3):680–4.CrossRefPubMedGoogle Scholar
  75. 75.
    McCormack L, Quiñónez E, Goldaracena N, et al. Liver transplantation using Chagas-infected donors in uninfected recipients: a single-center experience without prophylactic therapy. Am J Transplant. 2012;12(10):2832–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Vazquez MC, Riarte A, Pattin M, et al. Chagas’ disease can be transmitted through kidney transplantation. Transplant Proc. 1993;25:3259–60.PubMedGoogle Scholar
  77. 77.
    Zayas CF, Perlino C, Caliendo A, et al. Chagas disease after organ transplantation—United States, 2001. Morb Mortal Wkly Rep. 2002;51:210–2.Google Scholar
  78. 78.
    Souza FF, Castro-E-Silva O, Marin Neto JA, et al. Acute chagasic myocardiopathy after orthotopic liver transplantation with donor and recipient serologically negative for Trypanosoma cruzi: a case report. Transplant Proc. 2008;40(3):875–8.CrossRefPubMedGoogle Scholar
  79. 79.
    Alvar J, Vélez ID, Bern C, WHO Leishmaniasis Control Team, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5), e35671.PubMedCentralCrossRefPubMedGoogle Scholar
  80. 80.
    Evans TG. Leishmaniasis. Infect Dis Clin North Am. 1993;7:527–46.PubMedGoogle Scholar
  81. 81.
    Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol. 2008;10:1221–34.CrossRefPubMedGoogle Scholar
  82. 82.
    Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8(3):191–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Pavli A, Maltezou HC. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis. 2010;14:e1032–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Bart A, van Thiel PP, de Vries HJ, et al. Imported leishmaniasis in the Netherlands from 2005 to 2012: epidemiology, diagnostic techniques and sequence-based species typing from 195 patients. Euro Surveill. 2013;18:20544.CrossRefPubMedGoogle Scholar
  85. 85.
    Gautret P, Cramer JP, Field V, et al. EuroTravNet Network. Infectious diseases among travellers and migrants in Europe, EuroTravNet 2010. Euro Surveill. 2012;17(26). pii:20205.Google Scholar
  86. 86.
    Flores-Figueroa J, Okhuysen PC, von Sonnenburg F, et al. Patterns of illness in travelers visiting Mexico and Central America: the GeoSen-tinel experience. Clin Infect Dis. 2011;53:523–31.CrossRefPubMedGoogle Scholar
  87. 87.
    Perez-Ayala A, Norman F, Perez-Molina JA, et al. Imported leishmaniasis: a heterogeneous group of diseases. J Travel Med. 2009;16:395–401.CrossRefPubMedGoogle Scholar
  88. 88.
    Buonomano R, Brinkmann F, Leupin N, et al. Holiday souvenirs from the Mediterranean: three instructive cases of visceral leishmaniasis. Scand J Infect Dis. 2009;41:777–81.CrossRefPubMedGoogle Scholar
  89. 89.
    Ivanovski N, Popov Z, Cakalaroski K, et al. Living-unrelated (paid) renal transplantation—ten years later. Transplant Proc. 2005;37:563–4.CrossRefPubMedGoogle Scholar
  90. 90.
    Fishman JA. Pneumocystis carinii and parasitic infections in immunocompromised host. In: Rubin RH, Young LS, editors. Clinical approach to infection in the compromised host. 3rd ed. New York: Plenum Publishing; 1994. p. 275–334.CrossRefGoogle Scholar
  91. 91.
    Martin-Davila P, Fortun J, Lopez-Velez R, et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev. 2008;21:60–96.PubMedCentralCrossRefPubMedGoogle Scholar
  92. 92.
    Coster LO. Parasitic infections in solid organ transplant recipients. Infect Dis Clin North Am. 2013;27:395–427.CrossRefPubMedGoogle Scholar
  93. 93.
    Clemente W, Vidal E, Girão E, et al. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect. 2015;21(1):89–95.CrossRefPubMedGoogle Scholar
  94. 94.
    Hussein MM, Mooij JM, Roujouleh HM, et al. Non-typhoid Salmonella septicemia and visceral leishmaniasis in a renal transplant patient. Transplantation. 2001;71:479–81.CrossRefPubMedGoogle Scholar
  95. 95.
    Oliveira CM, Oliveira ML, Andrade SC, et al. Visceral leishmaniasis in renal transplant recipients: clinical aspects, diagnostic problems, and responses to treatment. Transplant Proc. 2008;40(3):755–60.CrossRefPubMedGoogle Scholar
  96. 96.
    Alves da Silva A, Pacheco-Silva A, de Castro Cintra Sesso R, et al. The risk factors for and effects of visceral leishmaniasis in graft and renal transplant recipients. Transplantation. 2013;95(5):721–7.CrossRefPubMedGoogle Scholar
  97. 97.
    Torregrosa JV, Ricart MJ, Montesinos M, et al. Visceral leishmaniasis-like cause of unexplained fever in a reno-pancreatic graft recipient. Nephron. 1993;65:318–9.CrossRefPubMedGoogle Scholar
  98. 98.
    Aardema H, Sijpkens YW, Visser LG. Pancytopenia in a simultaneous pancreas and kidney transplant: an unexpected cause–a case of visceral leishmaniasis in a transplant recipient. Clin Nephrol. 2009;71:460–2.CrossRefPubMedGoogle Scholar
  99. 99.
    Hernandez-Perez J, Yebra-Bango M, Jimenez-Martinez E, et al. Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review. Clin Infect Dis. 1999;29:918–21.CrossRefPubMedGoogle Scholar
  100. 100.
    Horber EF, Lerut JP, Reichen J, et al. Visceral leishmaniasis after orthotopic liver transplantation: impact of persistent splenomegaly. Transpl Int. 1993;6:55–7.CrossRefPubMedGoogle Scholar
  101. 101.
    Campos-Varela I, Len O, Castells L, et al. Visceral leishmaniasis among liver transplant recipients: an overview. Liver Transpl. 2008;14:1816–9.CrossRefPubMedGoogle Scholar
  102. 102.
    Frapier JM, Abraham B, Dereure J, et al. Fatal visceral leishmaniasis in a heart transplant recipient. J Heart Lung Transplant. 2001;20:912–3.CrossRefPubMedGoogle Scholar
  103. 103.
    Dantas Brito M, Campilho F, Branca R, et al. Visceral leishmaniasis: a differential diagnosis to remember after bone marrow transplantation. Case Rep Hematol. 2014;2014:587912.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Komitopoulou A, Tzenou T, Baltadakis J, et al. Is leishmaniasis an “unusual suspect” of infection in allogeneic transplantation? Transpl Infect Dis. 2014;16(6):1012–8.CrossRefPubMedGoogle Scholar
  105. 105.
    Drexler B, Holbro A. Unexpected bone marrow finding in a patient with pancytopenia after hematopoietic stem cell transplantation. Blood. 2014;124(5):678.PubMedCentralCrossRefPubMedGoogle Scholar
  106. 106.
    Martínez-Losada C, Martin C, Cuenca T, Torres A. Duodenal leishmaniasis after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48(4):614–5.CrossRefPubMedGoogle Scholar
  107. 107.
    Agteresch HJ, van 't Veer MB, Cornelissen JJ, Sluiters JF. Visceral leishmaniasis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40(4):391–3.Google Scholar
  108. 108.
    Sirvent-von Bueltzingsloewen A, Marty P, Rosenthal E, et al. Visceral leishmaniasis: a new opportunistic infection in hematopoietic stem-cell-transplanted patients. Bone Marrow Transplant. 2004;33(6):667–8.CrossRefPubMedGoogle Scholar
  109. 109.
    Sabbatini M, Pisani A, Ragosta A, et al. Visceral leishmaniasis in renal transplant recipients: is it still a challenge to the nephrologist? Transplantation. 2002;73:299–301.CrossRefPubMedGoogle Scholar
  110. 110.
    Almeida S, Nascentes T, Demas M. Colonic leishmaniasis followed by liver transplantation. Am J Trop Med Hyg. 2010;83:209.CrossRefGoogle Scholar
  111. 111.
    Vargas Acosta AM, Belchí Segura E, Martinez Caselles A, et al. [Diarrhea due to visceral leishmaniasis in a liver transplant recipient]. Gastroenterol Hepatol. 2013;36(4):271–3 (Spanish).Google Scholar
  112. 112.
    Jokipii L, Salmela K, Saha H, et al. Leishmaniasis diagnosed from bronchoalveolar lavage. Scand J Infect Dis. 1992;24:677–81.CrossRefPubMedGoogle Scholar
  113. 113.
    Dettwiler S, McKee T, Hadaya K, et al. Visceral leishmaniasis in a kidney transplant recipient: parasitic interstitial nephritis, a cause of renal dysfunction. Am J Transplant. 2010;10:1486–9.CrossRefPubMedGoogle Scholar
  114. 114.
    Simon I, Wissing KM, Del Marmol V, et al. Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature. Transpl Infect Dis. 2011;13(4):397–406.CrossRefPubMedGoogle Scholar
  115. 115.
    Ma DD, Concannon AJ, Hayes J. Fatal leishmaniasis in renal transplant patient. Lancet. 1979;2:311–2.CrossRefPubMedGoogle Scholar
  116. 116.
    Roustan G, Jimenez JA, Gutierrez-Solar B, et al. Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B. Br J Dermatol. 1998;138:526–8.CrossRefPubMedGoogle Scholar
  117. 117.
    Golino A, Duncan JM, Zeluff B, et al. Leishmaniasis in a heart transplant patient. J Heart Lung Transplant. 1992;11:820–3.PubMedGoogle Scholar
  118. 118.
    Venencie PY, Bouree P, Hiesse C, et al. [Disseminated cutaneous leishmaniasis in a case of an immunosuppressed woman.] Ann Dermatol Venereol. 1993;120:461–3 (French).Google Scholar
  119. 119.
    Alrajhi AA, Saleem M, Ibrahim EA, et al. Leishmaniasis of the tongue in a renal transplant recipient. Clin Infect Dis. 1998;27:1332–3.CrossRefPubMedGoogle Scholar
  120. 120.
    Borgia F, Vaccaro M, Guarneri F, et al. Mucosal leishmaniasis occurring in a renal transplant recipient. Dermatology. 2001;202:266–7.CrossRefPubMedGoogle Scholar
  121. 121.
    Iborra C, Caumes E, Carrière J, et al. Mucosal leishmaniasis in a heart transplant recipient. Br J Dermatol. 1998;138:190–2.CrossRefPubMedGoogle Scholar
  122. 122.
    Ramos A, Múñez E, García-Domínguez J, et al. Mucosal leishmaniasis mimicking squamous cell carcinoma in a liver transplant recipient. Transpl Infect Dis. 2015;17:488–92. doi: 10.1111/tid.12380.CrossRefPubMedGoogle Scholar
  123. 123.
    Hide M, Singh R, Kumar B, Bañuls AL, Sundar S. A microculture technique for isolating live Leishmania parasites from peripheral blood of visceral leishmaniasis patients. Acta Trop. 2007;102(3):197–200.CrossRefPubMedGoogle Scholar
  124. 124.
    Carvalho SF, Lemos EM, Corey R, et al. Performance of recombinant k-39 antigen in the diagnosis of Brazilian leishmaniasis. Am J Trop Med Hyg. 2003;68:321–4.PubMedGoogle Scholar
  125. 125.
    de Oliveira CI, Bafica A, Oliveira F, et al. Clinical utility of polymerase chain reaction-based detection of Leishmania in the diagnosis of American cutaneous leishmaniasis. Clin Infect Dis. 2003;37:e149–53.CrossRefPubMedGoogle Scholar
  126. 126.
    Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999;28:42–8.CrossRefPubMedGoogle Scholar
  127. 127.
    Boletis JN, Pefanis A, Stathakis C, et al. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1999;28:1308–9.CrossRefPubMedGoogle Scholar
  128. 128.
    van Griensven J, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet. 2011;377(9764):443–4.CrossRefPubMedGoogle Scholar
  129. 129.
    Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011;11(4):322–5.CrossRefPubMedGoogle Scholar
  130. 130.
    Tsiodras S, Zafiropoulou R, Giotakis J, et al. Deep sinus aspergillosis in a liver transplant recipient successfully treated with a combination of caspofungin and voriconazole. Transpl Infect Dis. 2004;6:37–40.CrossRefPubMedGoogle Scholar
  131. 131.
    Harzallah K, Belhadj R, Jemli B, et al. Visceral leishmaniasis in a renal transplant recipient treated with allopurinol. Saudi J Kidney Dis Transpl. 2010;21(1):105–8.PubMedGoogle Scholar
  132. 132.
    World Health Organization. Control of the leishmaniasis. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO technical report series 949 (2010). Geneva: WHO; 2010.Google Scholar
  133. 133.
    Clemente WT, Rabello A, Faria LC, et al. High prevalence of asymptomatic Leishmania spp. infection among liver transplant recipients and donors from an endemic area of Brazil. Am J Transplant. 2014;14:96–101.CrossRefPubMedGoogle Scholar
  134. 134.
    White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis. 2008;46:165–71.CrossRefGoogle Scholar
  135. 135.
    Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415:680–5.CrossRefPubMedGoogle Scholar
  136. 136.
    Hay SI, Guerra CA, Tatem AJ, et al. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis. 2004;4(6):327–36.PubMedCentralCrossRefPubMedGoogle Scholar
  137. 137.
    Andriopoulos P, Economopoulou A, Spanakos G, Assimakopoulos G. A local outbreak of autochthonous Plasmodium vivax malaria in Laconia, Greece—a re-emerging infection in the southern borders of Europe? Int J Infect Dis. 2013;17(2):e125–8.CrossRefPubMedGoogle Scholar
  138. 138.
    Kitchen A, Mijovic A, Hewitt P. Transfusion-transmitted malaria: current donor selection guidelines are not sufficient. Vox Sang. 2005;88(3):200–1.CrossRefPubMedGoogle Scholar
  139. 139.
    Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001;344:1973–8.CrossRefPubMedGoogle Scholar
  140. 140.
    Türkmen A, Sever MS, Ecder T, et al. Post transplant malaria. Transplantation. 1996;62:1521–3.CrossRefPubMedGoogle Scholar
  141. 141.
    Fischer L, Sterneck M, Claus M, et al. Transmission of malaria tertiana by multi-organ donation. Clin Transpl. 1999;13:492–6.CrossRefGoogle Scholar
  142. 142.
    Talabiska DG, Komar MJ, Wytock DH, Rubin RA. Post-transfusion acquired malaria complicating orthotopic liver transplantation. Am J Gastroenterol. 1996;91:376–9.PubMedGoogle Scholar
  143. 143.
    Pandey D, Lee KH, Wong SY, Tan KC. Malaria after liver transplantation: report of two cases. Hepatobiliary Pancreat Dis Int. 2008;7(2):210–3.PubMedGoogle Scholar
  144. 144.
    Hung CC, Chang SC, Chen YC, et al. Plasmodium vivax infection in a renal transplant recipient: report of a case. J Formos Med Assoc. 1994;93:888–9.PubMedGoogle Scholar
  145. 145.
    Elsharif ME, Malik EM, Imam ME, Omran MO, Elsharif EG. Malaria incidence among kidney-transplanted recipients in an endemic malaria area, Sudan. Saudi J Kidney Dis Transpl. 2012;23(5):1099–103.CrossRefPubMedGoogle Scholar
  146. 146.
    Holzer B, Glück Z, Zambelli D, et al. Transmission of malaria by renal transplantation. Transplantation. 1985;39:315–6.CrossRefPubMedGoogle Scholar
  147. 147.
    Lee PC, Lee PY, Lei FF, et al. Malaria infection in kidney transplant recipients. Transplant Proc. 1994;26:2099–100.PubMedGoogle Scholar
  148. 148.
    Schwartz BS, Mawhorter SD; AST Infectious Diseases Community of Practice. Parasitic infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):280–303.Google Scholar
  149. 149.
    Tan HW, Ch’ng SL. Drug interaction between cyclosporine A and quinine in a renal transplant patient with malaria. Singapore Med J. 1991;32(3):189–90.PubMedGoogle Scholar
  150. 150.
    Salutari P, Sica S, Chiusolo P, Micciulli G, Plaisant P, Nacci A, Antinori A, Leone G. Plasmodium vivax malaria after autologous bone marrow transplantation: an unusual complication. Bone Marrow Transplant. 1996;18(4):805–6.PubMedGoogle Scholar
  151. 151.
    Dharmasena F, Gordon-Smith EC. Transmission of malaria by bone marrow transplantation. Transplantation. 1986;42(2):228.CrossRefPubMedGoogle Scholar
  152. 152.
    Lefrère F, Besson C, Datry A, et al. Transmission of Plasmodium falciparum by allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;18(2):473–4.PubMedGoogle Scholar
  153. 153.
    Tran VB, Tran VB, Lin KH. Malaria infection after allogeneic bone marrow transplantation in a child with thalassemia. Bone Marrow Transplant. 1997;19(12):1259–60.CrossRefPubMedGoogle Scholar
  154. 154.
    O’Donnell J, Goldman JM, Wagner K, Ehinger G, Martin N, Leahy M, Kariuki N, Dokal I, Roberts I. Donor-derived Plasmodium vivax infection following volunteer unrelated bone marrow transplantation. Bone Marrow Transplant. 1998;21(3):313–4.CrossRefPubMedGoogle Scholar
  155. 155.
    Raina V, Sharma A, Gujral S, Kumar R. Plasmodium vivax causing pancytopenia after allogeneic blood stem cell transplantation in CML. Bone Marrow Transplant. 1998;22(2):205–6.CrossRefPubMedGoogle Scholar
  156. 156.
    Villeneuve L, Cassaing S, Magnaval JF, et al. Plasmodium falciparum infection following allogeneic bone-marrow transplantation. Ann Trop Med Parasitol. 1999;93(5):533–5.Google Scholar
  157. 157.
    Abdelkefi A, Ben Othman T, Torjman L, et al. Plasmodium falciparum causing hemophagocytic syndrome after allogeneic blood stem cell transplantation. Hematol J. 2004;5(5):449–50.CrossRefPubMedGoogle Scholar
  158. 158.
    Yenen OS, Keskin K, Cavuşlu S, et al. A case of Plasmodium vivax infection transmitted by renal allograft. Nephrol Dial Transplant. 1994;9(12):1805–6.PubMedGoogle Scholar
  159. 159.
    Chiche L, Lesage A, Duhamel C, et al. Posttransplant malaria: first case of transmission of Plasmodium falciparum from a white multiorgan donor to four recipients. Transplantation. 2003;75(1):166–8.CrossRefPubMedGoogle Scholar
  160. 160.
    Sabé N, González-Costello J, Oriol I, et al. Donor-transmitted malaria after heart transplant managed successfully with artesunate. Transpl Infect Dis. 2014;16(6):999–1002.CrossRefPubMedGoogle Scholar
  161. 161.
    White NJ. The treatment of malaria. N Engl J Med. 1996;335:800–6.CrossRefPubMedGoogle Scholar
  162. 162.
    Bemelman F, De Blok K, De Vries P, Surachno S, Ten Berge I. Falciparum malaria transmitted by a thick blood smear negative kidney donor. Scand J Infect Dis. 2004;36(10):769–71.CrossRefPubMedGoogle Scholar
  163. 163.
    Snounou G, Viriyakosol S, Zhu XP, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315–20.CrossRefPubMedGoogle Scholar
  164. 164.
    World Health Organization. Guidelines for the treatment of malaria, 3rd edition. Geneva: WHO; 2015. Accessed 1 June 2015.
  165. 165.
    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.PubMedCentralCrossRefPubMedGoogle Scholar
  166. 166.
    Anteyi EA, Liman HM, Gbaji A. Malaria prophylaxis in post renal transplant recipients in the tropics: is it necessary? Cent Afr J Med. 2003;49(5–6):63–6.PubMedGoogle Scholar
  167. 167.
    Hildebrandt A, Gray JS, Hunfeld KP. Human babesiosis in Europe: what clinicians need to know. Infection. 2013;41(6):1057–72.CrossRefPubMedGoogle Scholar
  168. 168.
    Weiss LM, Wittner M, Tanowitz HB. The treatment of babesiosis. N Engl J Med. 2001;344(10):773.CrossRefPubMedGoogle Scholar
  169. 169.
    Cirino C, Fitzhugh C, Tisdale J, et al. Transfusion-associated babesiosis with an atypical time course after nonmyeloablative transplantation for sickle cell disease. Ann Intern Med. 2008;148(10):794–5.PubMedCentralCrossRefPubMedGoogle Scholar
  170. 170.
    Perdrizet G, Olson N, Krause P, et al. Babesiosis in a renal transplant recipient acquired through blood transfusion. Transplantation. 2000;70:205–7.PubMedGoogle Scholar
  171. 171.
    Lubin AS, Snydman DR, Miller KB. Persistent babesiosis in a stem cell transplant recipient. Leuk Res. 2011;35(6):e77–8.CrossRefPubMedGoogle Scholar
  172. 172.
    Slovut D, Benedetti E, Matas A. Babesiosis and hemophagocytic syndrome in an asplenic renal transplant recipient. Transplantation. 1996;62:537–45.CrossRefPubMedGoogle Scholar
  173. 173.
    Atias A. Estrongiloidiasis. In: Atias A, editor. Parasitologia clinica. 3rath ed. Santiago, Chile: Publicaciones Tecnicas Mediterraneo; 1991. p. 181–3.Google Scholar
  174. 174.
    Genta RM. Global prevalence of strongyloidiasis: critical review with epidemiologic insight into prevention of disseminated disease. Rev Infect Dis. 1989;11:755–67.CrossRefPubMedGoogle Scholar
  175. 175.
    Schär F, Trostdorf U, Giardina F, et al. Strongyloides stercoralis: global distribution and risk factors. PLoS Negl Trop Dis. 2013;7(7), e2288.PubMedCentralCrossRefPubMedGoogle Scholar
  176. 176.
    Lindo JF, Lee MG. Strongyloides stercoralis and S. fulleborni. In: Gillespie S, Pearson R, editors. Principles and practice of parasitology. New York: Wiley; 2001. p. 479–500.CrossRefGoogle Scholar
  177. 177.
    Liu LX, Weller PF. Strongyloidiasis and other intestinal nematode infections. Infect Dis Clin North Am. 1993;7:655–82.PubMedGoogle Scholar
  178. 178.
    Weiser JA, Scully BE, Bulman WA, et al. Periumbilical parasitic thumbprint purpura: strongyloides hyperinfection syndrome acquired from a cadaveric renal transplant. Transpl Infect Dis. 2011;13(1):58–62.CrossRefPubMedGoogle Scholar
  179. 179.
    DeVault Jr GA, King JW, Rohr MS, et al. Opportunistic infections with Strongyloides stercoralis in renal transplantation. Rev Infect Dis. 1990;12:653–71.CrossRefPubMedGoogle Scholar
  180. 180.
    Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis. 2009;49(9):1411–23.PubMedCentralCrossRefPubMedGoogle Scholar
  181. 181.
    Wirk B, Wingard JR. Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11(2):143–8.CrossRefPubMedGoogle Scholar
  182. 182.
    Izquierdo I, Briones J, Lluch R, Arqueros C, Martino R. Fatal strongyloides hyperinfection complicating a gram-negative sepsis after allogeneic stem cell transplantation: a case report and review of the literature. Case Rep Hematol. 2013;2013:860976.PubMedCentralPubMedGoogle Scholar
  183. 183.
    Abanyie FA, Gray EB, Delli Carpini KW, et al. Donor-derived strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009–2013. Am J Transplant. 2015;15(5):1369–75.PubMedCentralCrossRefPubMedGoogle Scholar
  184. 184.
    Roseman DA, Kabbani D, Kwah J, et al. Strongyloides stercoralis transmission by kidney transplantation in two recipients from a common donor. Am J Transplant. 2013;13(9):2483–6.PubMedCentralCrossRefPubMedGoogle Scholar
  185. 185.
    Ferreira CJ, Silva DA, Almeida PH, et al. Fatal disseminated strongyloidiasis after kidney transplantation. Rev Soc Bras Med Trop. 2012;45(5):652–4.CrossRefPubMedGoogle Scholar
  186. 186.
    Mokaddas EM, Shati S, Abdulla A, et al. Fatal strongyloidiasis in three kidney recipients in Kuwait. Med Princ Pract. 2009;18(5):414–7.CrossRefPubMedGoogle Scholar
  187. 187.
    Said T, Nampoory MR, Nair MP, et al. Hyperinfection strongyloidiasis: an anticipated outbreak in kidney transplant recipients in Kuwait. Transplant Proc. 2007;39(4):1014–5.CrossRefPubMedGoogle Scholar
  188. 188.
    Lichtenberger P, Rosa-Cunha I, Morris M, et al. Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin. Transpl Infect Dis. 2009;11(2):137–42.CrossRefPubMedGoogle Scholar
  189. 189.
    Vilela EG, Clemente WT, Mira RR, et al. Strongyloides stercoralis hyperinfection syndrome after liver transplantation: case report and literature review. Transpl Infect Dis. 2009;11(2):132–6.CrossRefPubMedGoogle Scholar
  190. 190.
    Schaeffer MW, Buell JF, Gupta M, et al. Strongyloides hyperinfection syndrome after heart transplantation: case report and review of the literature. J Heart Lung Transplant. 2004;23(7):905–11.CrossRefPubMedGoogle Scholar
  191. 191.
    Mizuno S, Iida T, Zendejas I, et al. Strongyloides hyperinfection syndrome following simultaneous heart and kidney transplantation. Transpl Int. 2009;22(2):251–3.CrossRefPubMedGoogle Scholar
  192. 192.
    El Masry HZ, O’Donnell J. Fatal stongyloides hyperinfection in heart transplantation. J Heart Lung Transplant. 2005;24(11):1980–3.CrossRefPubMedGoogle Scholar
  193. 193.
    Iori AP, Ferretti A, Gentile G, et al. Strongyloides stercoralis infection in allogeneic stem cell transplant: a case report and review of the literature. Transpl Infect Dis. 2014;16(4):625–30.CrossRefPubMedGoogle Scholar
  194. 194.
    Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep. 2008;10(2):105–10.PubMedCentralCrossRefPubMedGoogle Scholar
  195. 195.
    Zaha O, Hirata T, Uchima N, Kinjo F, Saito A. Comparison of anthelmintic effects of two doses of ivermectin on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody. J Infect Chemother. 2004;10(6):348–51.CrossRefPubMedGoogle Scholar
  196. 196.
    Gann PH, Neva FA, Gam AA. A randomized trial of single and two dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis. 1994;169:1076–9.CrossRefPubMedGoogle Scholar
  197. 197.
    Marti H, Haji HJ, Savioli L. A comparative trial of single dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminths infections in children. Am J Trop Med Hyg. 1996;55:477–81.CrossRefPubMedGoogle Scholar
  198. 198.
    Ashraf M, Gue CL, Baddour LM. Case report: strongyloidiasis refractory to treatment with ivermectin. Am J Med Sci. 1996;311:178–9.PubMedGoogle Scholar
  199. 199.
    Khuroo MS. Hyperinfection strongyloidiasis in renal transplant recipients. BMJ Case Rep. 2014;2014. pii: bcr2014205068.Google Scholar
  200. 200.
    Le M, Ravin K, Hasan A, et al. Single donor-derived strongyloidiasis in three solid organ transplant recipients: case series and review of the literature. Am J Transplant. 2014;14(5):1199–206.CrossRefPubMedGoogle Scholar
  201. 201.
    Rodriguez-Hernandez MJ, Ruiz-Perez-Pipaon M, Cañas E, Bernal C, Gavilan F. Strongyloides stercoralis hyperinfection transmitted by liver allograft in a transplant recipient. Am J Transplant. 2009;9(11):2637–40.CrossRefPubMedGoogle Scholar
  202. 202.
    Huston JM, Eachempati SR, Rodney JR, et al. Treatment of Strongyloides stercoralis hyperinfection-associated septic shock and acute respiratory distress syndrome with drotrecogin alfa (activated) in a renal transplant recipient. Transpl Infect Dis. 2009;11(3):277–80.CrossRefPubMedGoogle Scholar
  203. 203.
    Balagopal A, Mills L, Shah A, Subramanian A. Detection and treatment of Strongyloides hyperinfection syndrome following lung transplantation. Transpl Infect Dis. 2009;11(2):149–54.CrossRefPubMedGoogle Scholar
  204. 204.
    Mejia R, Nutman TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis. 2012;25(4):458–63.PubMedCentralCrossRefPubMedGoogle Scholar
  205. 205.
    Tarr PE, Miele PS, Peregoy KS, et al. Case report: rectal administration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg. 2003;68(4):453–5.PubMedGoogle Scholar
  206. 206.
    Bogoch II, Khan K, Abrams H, et al. Failure of Ivermectin per rectum to achieve clinically meaningful serum levels in two cases of strongyloides hyperinfection. Am J Trop Med Hyg. 2015;93:94–6.Google Scholar
  207. 207.
    Grein JD, Mathisen GE, Donovan S, Fleckenstein L. Serum ivermectin levels after enteral and subcutaneous administration for Strongyloides hyperinfection: a case report. Scand J Infect Dis. 2010;42(3):234–6.CrossRefPubMedGoogle Scholar
  208. 208.
    Hirata T, Uchima N, Kishimoto K, et al. Impairment of host immune response against Strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am J Trop Med Hyg. 2006;74:246–9.PubMedGoogle Scholar
  209. 209.
    Buonfrate D, Formenti F, Perandin F, Bisoffi Z. Novel approaches to the diagnosis of Strongyloides stercoralis infection. Clin Microbiol Infect. 2015;21:543–52. doi: 10.1016/j.cmi.2015.04.001. pii: S1198-743X(15)00387-0.
  210. 210.
    Rodriguez EA, Abraham T, Williams FK. Severe strongyloidiasis with negative serology after corticosteroid treatment. Am J Case Rep. 2015;16:95–8.PubMedCentralCrossRefPubMedGoogle Scholar
  211. 211.
    Abdul-Fattah MM, Nasr ME, Yousef SM, Ibraheem MI, Abdul-Wahhab SE, Soliman HM. Efficacy of ELISA in diagnosis of strongyloidiasis among the immune-compromised patients. J Egypt Soc Parasitol. 1995;25(2):491–8.PubMedGoogle Scholar
  212. 212.
    Marcos LA, Terashima A, Dupont HL, et al. Strongyloides hyperinfection syndrome: en emerging global infectious disease. Trans R Soc Trop Med Hyg. 2008;102(4):314–8.CrossRefPubMedGoogle Scholar
  213. 213.
    de Kaminsky RG. Evaluation of three methods for laboratory diagnosis of Strongyloides stercoralis infection. J Parasitol. 1993;79:277–80.CrossRefPubMedGoogle Scholar
  214. 214.
    Sato Y, Kobayashi J, Toma H, et al. Efficacy of stool examination for detection of Strongyloides infection. Am J Trop Med Hyg. 1995;53:248–50.CrossRefPubMedGoogle Scholar
  215. 215.
    Repetto SA, Alba Soto CD, Cazorla SI, Tayeldin ML, Cuello S, Lasala MB, Tekiel VS, González Cappa SM. An improved DNA isolation technique for PCR detection of Strongyloides stercoralis in stool samples. Acta Trop. 2013;126(2):110–4.CrossRefPubMedGoogle Scholar
  216. 216.
    Beal CB, Viens P, Grant RG. A new technique for sampling duodenal contents: demonstration of upper small bowel pathogens. Am J Trop Med Hyg. 1970;19:349–52.CrossRefPubMedGoogle Scholar
  217. 217.
    World Health Organization. Available at Accessed 31 May 2015.
  218. 218.
    Sobh MA, el-Agroudy AE, Moustafa FE, et al. Impact of schistosomiasis on patient and graft outcome after kidney transplantation. Nephrol Dial Transplant. 1992;7:858–64.Google Scholar
  219. 219.
    Mahmoud KM, Sobh MA, El-Agroudy AE, et al. Impact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years’ follow-up. Nephrol Dial Transplant. 2001;16:2214–21.CrossRefPubMedGoogle Scholar
  220. 220.
    Barrou B, Bitker MO, Boyer C, et al. Results of renal transplantation in patients with Schistosoma infection. J Urol. 1997;157:1232–6.CrossRefPubMedGoogle Scholar
  221. 221.
    Muñoz P, Valerio M, Puga D, Bouza E. Parasitic infections in solid organ transplant recipients. Infect Dis Clin North Am. 2010;24(2):461–95.CrossRefPubMedGoogle Scholar
  222. 222.
    Bell A, Roberts HC, Chappell LH. The antiparasitic effects of cyclosporine A: possible drug and clinical applications. Gen Pharmacol. 1996;27:963–71.CrossRefPubMedGoogle Scholar
  223. 223.
    Bout DT, Deslee D, Capron AR. Protection against schistosomiasis produced by cyclosporine A. Am J Trop Med Hyg. 1984;33:185–6.CrossRefPubMedGoogle Scholar
  224. 224.
    Caffrey CR, Gsell C, Ruppel A. Schistosoma japonicum is less sensitive to cyclosporine A in vivo than Schistosoma mansoni. J Parasitol. 1999;85:736–9.CrossRefPubMedGoogle Scholar
  225. 225.
    Azevedo LS, de Paula FJ, Ianhez LE, et al. Renal transplantation and Schistosomiasis mansoni. Transplantation. 1987;44:795–8.CrossRefPubMedGoogle Scholar
  226. 226.
    Hoare M, Gelson WT, Davies SE, Curran M, Alexander GJ. Hepatic and intestinal schistosomiasis after orthotopic liver transplant. Liver Transpl. 2005;11(12):1603–7.CrossRefPubMedGoogle Scholar
  227. 227.
    Van-Lume DS, Albuquerque Mde F, Souza AI, et al. Association between Schistosomiasis mansoni and hepatitis C: systematic review. Rev Saude Publica. 2013;47(2):414–24.CrossRefPubMedGoogle Scholar
  228. 228.
    Pannegeon V, Masini JP, Paye F, Chazouillères O, Girard PM. Schistosoma mansoni infection and liver graft. Transplantation. 2005;80(2):287.CrossRefPubMedGoogle Scholar
  229. 229.
    Pungpapong S, Krishna M, Abraham SC, et al. Clinicopathologic findings and outcomes of liver transplantation using grafts from donors with unrecognized and unusual diseases. Liver Transpl. 2006;12:310–5.CrossRefPubMedGoogle Scholar
  230. 230.
    Vincenzi R, Neto JS, Fonseca EA, et al. Schistosoma mansoni infection in the liver graft: the impact on donor and recipient outcomes after transplantation. Liver Transpl. 2011;17(11):1299–303.CrossRefPubMedGoogle Scholar
  231. 231.
    Andraus W, Pugliese V, Pecora R, D’Albuquerque LA. Intentional use of Schistosoma mansoni-infected grafts in living donor liver transplantation. Liver Transpl. 2012;18(7):867–8.CrossRefPubMedGoogle Scholar
  232. 232.
    Hefty TR, McCorkell SJ. Schistosomiasis and renal transplantation. J Urol. 1986;135:858–64.CrossRefGoogle Scholar
  233. 233.
    Sobh MA, el Sharkawy SE, Shokier AA, et al. Effects of schistosomiasis on living kidney donors. Scand J Urol Nephrol. 1992;26:409–12.CrossRefPubMedGoogle Scholar
  234. 234.
    Soentjens P, Clerinx J. Treatment and prevention of schistosomiasis. In UpToDate, Weller PF (Ed), UpToDate, Waltham, MA. Accessed 4 June 2015.Google Scholar
  235. 235.
    Godawska-Matysik A, Kieć-Kononowicz K. Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). Acta Pol Pharm. 2006;63(5):381–5.PubMedGoogle Scholar
  236. 236.
    King CH. Cestodes. In: Mandell G, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000. p. 2956–65.Google Scholar
  237. 237.
    Moro PL. Clinical manifestations and diagnosis of echinococcosis. In UpToDate Weller PF (Ed) UpToDate, Waltham, MA. Accessed 4 June 2015.Google Scholar
  238. 238.
    World Health Organization. Guidelines for treatment of cystic and alveolar echinococcosis in humans. Informal Working Group on Echinococcosis. Bull World Health Organ. 1996;74:231–42.Google Scholar
  239. 239.
    Kim J, Delioukina ML, Lee W, et al. Successful allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia in a patient with hepatic echinococcal cyst managed by delayed hepatectomy. Transpl Infect Dis. 2011;13(3):273–77.Google Scholar
  240. 240.
    Kern P, Grüner B, Wahlers K. Diagnosis and course of echinococcocal diseases in the transplant setting. Transpl Infect Dis. 2011;13(3):217–21.CrossRefPubMedGoogle Scholar
  241. 241.
    Loinaz C, Moreno-González E, Gómez R, et al. Liver transplantation in liver disease: Echinococcus granulosus. Transplant Proc. 1998;30(7):3268–9.CrossRefPubMedGoogle Scholar
  242. 242.
    Loinaz C, González EM, Jiménez C, et al. Long-term biliary complications after liver surgery leading to liver transplantation. World J Surg. 2001;25(10):1260–3.CrossRefPubMedGoogle Scholar
  243. 243.
    Moreno-González E, Loinaz Segurola C, García Ureña MA, et al. Liver transplantation for Echinococcus granulosus hydatid disease. Transplantation. 1994;58(7):797–800.CrossRefPubMedGoogle Scholar
  244. 244.
    Chomicz L, Szubert A, Fiedor P, et al. Human cystic and alveolar echinococcoses as indication to liver transplantation. Transplant Proc. 2003;35(6):2260–1.CrossRefPubMedGoogle Scholar
  245. 245.
    Özdemir M, Ringe KI, Schrem H, et al. A case of successful renal transplantation for hydatid disease after surgical treatment of disseminated cysts. Transpl Infect Dis. 2015;17:406–10.CrossRefPubMedGoogle Scholar
  246. 246.
    Cavdar C, Celik A, Saglam F, et al. Isolated hydatid disease of the native kidney in a renal transplant recipient. Nephrol Dial Transplant. 2007;22(2):656–7.CrossRefPubMedGoogle Scholar
  247. 247.
    Palmiero G, Ciampi R, Gallo R, Federico S, Sabbatini M. Liver echinococcosis in a renal transplant patient: a particularly intriguing case report. J Nephrol. 2008;21(3):442–5.PubMedGoogle Scholar
  248. 248.
    Bhat RA, Wani I, Khan I, Wani M. Renal allograft transplant recipient with ruptured hydatid native kidney. Urol Ann. 2014;6(3):267–9.PubMedCentralCrossRefPubMedGoogle Scholar
  249. 249.
    Aghajanzadeh M, Monfared A, Mokhtari GR, et al. Pulmonary hydatid cyst and successful renal transplantation. Med J Islam Repub Iran. 2009;23:48–52.Google Scholar
  250. 250.
    Sobrino JM, Pulpón LA, Crespo MG, et al. Heart transplantation in a patient with liver hydatidosis. J Heart Lung Transplant. 1993;12:531–3.PubMedGoogle Scholar
  251. 251.
    Jimenez Romero C, Moreno Gonzalez E, Garcia Garcia I, et al. Successful transplantation of a liver graft with a calcified hydatid cyst after back-table resection. Transplantation. 1995;60(8):883–4.CrossRefPubMedGoogle Scholar
  252. 252.
    Bein T, Haerty W, Haller M, et al. Organ selection in intensive care: transplantation of a liver allograft, including calcified cyst of Echinococcus granularis. Intensive Care Med. 1993;19(3):182.CrossRefPubMedGoogle Scholar
  253. 253.
    Eris C, Akbulut S, Sakcak I, Kayaalp C, Ara C, Yilmaz S. Liver transplant with a marginal donor graft containing a hydatid cyst-a case report. Transplant Proc. 2013;45(2):828–30.CrossRefPubMedGoogle Scholar
  254. 254.
    Koch S, Bresson-Hadni S, Miguet JP, et al. Experience of liver transplantation for incurable alveolar echinococcosis: a 45-case European collaborative report. Transplantation. 2003;75:856–63.CrossRefPubMedGoogle Scholar
  255. 255.
    Seas C, Bravo F. Free-living amebas. In: UpToDate, Weller PF (Ed). UpToDate, Waltham, MA. Accessed 30 May 2015.Google Scholar
  256. 256.
    Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis. 2007;44(2):204–12.CrossRefPubMedGoogle Scholar
  257. 257.
    Centers for Disease Control and Prevention (CDC). Balamuthia mandrillaris transmitted through organ transplantation—Mississippi, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(36):1165–70.Google Scholar
  258. 258.
    Centers for Disease Control and Prevention (CDC). Notes from the field: transplant-transmitted Balamuthia mandrillaris—Arizona, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(36):1182.Google Scholar
  259. 259.
    Gupte AA, Hocevar SN, Lea AS, et al. Transmission of Balamuthia mandrillaris through solid organ transplantation: utility of organ recipient serology to guide clinical management. Am J Transplant. 2014;14(6):1417–24.PubMedCentralCrossRefPubMedGoogle Scholar
  260. 260.
    Satlin MJ, Graham JK, Visvesvara GS, et al. Fulminant and fatal encephalitis caused by Acanthamoeba in a kidney transplant recipient: case report and literature review. Transpl Infect Dis. 2013;15(6):619–26.CrossRefPubMedGoogle Scholar
  261. 261.
    Feingold JM, Abraham J, Bilgrami S, et al. Acanthamoeba meningoencephalitis following autologous peripheral stem cell transplantation. Bone Marrow Transplant. 1998;22(3):297–300.CrossRefPubMedGoogle Scholar
  262. 262.
    Anderlini P, Przepiorka D, Luna M, et al. Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone Marrow Transplant. 1994;14(3):459–61.PubMedGoogle Scholar
  263. 263.
    Kaul DR, Lowe L, Visvesvara GS, et al. Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole. Transpl Infect Dis. 2008;10(6):437–41.CrossRefPubMedGoogle Scholar
  264. 264.
    Qvarnstrom Y, Visvesvara GS, Sriram R, da Silva AJ. Multiplex realtime PCR assay for simultaneous detection of Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri. J Clin Microbiol. 2006;44:3589–95.PubMedCentralCrossRefPubMedGoogle Scholar
  265. 265.
    Fung KT, Dhillon AP, McLaughlin JE, et al. Cure of Acanthamoeba cerebral abscess in a liver transplant patient. Liver Transpl. 2008;14(3):308–12.CrossRefPubMedGoogle Scholar
  266. 266.
    Orozco L, Hanigan W, Khan M, Fratkin J, Lee M. Neurosurgical intervention in the diagnosis and treatment of Balamuthia mandrillaris encephalitis. J Neurosurg. 2011;115(3):636–40.CrossRefPubMedGoogle Scholar
  267. 267.
    Roy SL, Metzger R, Chen JG, et al. Risk for transmission of Naegleria fowleri from solid organ transplantation. Am J Transplant. 2014;14(1):163–71.CrossRefPubMedGoogle Scholar
  268. 268.
    Leder K, Weller PF. Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis. In: UpToDate, Ryan ET, Mitty J (Ed), UpToDate, Waltham, MA. Accessed 23 May 2015.Google Scholar
  269. 269.
    Guerrant RL. Cryptosporidiosis: an emerging, highly infectious threat. Emerg Infect Dis. 1997;3:51–7.PubMedCentralCrossRefPubMedGoogle Scholar
  270. 270.
    Hong DK, Wong CJ, Gutierrez K. Severe cryptosporidiosis in a seven-year old renal transplant recipient: case report and review of the literature. Pediatr Transplant. 2007;11(1):94–100.CrossRefPubMedGoogle Scholar
  271. 271.
    Chieffi PP, Sens YA, Paschoalotti MA, et al. Infection by Cryptosporidium parvum in renal patients submitted to renal transplant or hemodialysis. Rev Soc Bras Med Trop. 1998;31:333–7 (Portuguese).Google Scholar
  272. 272.
    Ok UZ, Cirit M, Uner A, et al. Cryptosporidiosis and blastocystosis in renal transplant recipients. Nephron. 1997;75:171–4.CrossRefPubMedGoogle Scholar
  273. 273.
    Bhadauria D, Goel A, Kaul A, et al. Cryptosporidium infection after renal transplantation in an endemic area. Transpl Infect Dis. 2015;17(1):48–55.CrossRefPubMedGoogle Scholar
  274. 274.
    Sears CL, Kirkpatrick BD. Cryptosporidiosis and isosporiasis. In: Gillespie S, Pearson R, editors. Principles and practice of parasitology. New York: Wiley; 2001. p. 139–64.CrossRefGoogle Scholar
  275. 275.
    Ungar BL. Cryptosporium. In: Mandell G, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000. p. 2903–15.Google Scholar
  276. 276.
    Current WL. Cryptosporidium parvum: household transmission. Ann Intern Med. 1994;120:518–9.CrossRefPubMedGoogle Scholar
  277. 277.
    Juranek D. Cryptosporidiosis: sources of infection and guidelines for prevention. Clin Infect Dis. 1995;21:S57–61.CrossRefPubMedGoogle Scholar
  278. 278.
    Meinhardt PL, Casemore DP, Miller KB. Epidemiologic aspects of human cryptosporidiosis and the role of waterborne transmission. Epidemiol Rev. 1996;18:118–36.CrossRefPubMedGoogle Scholar
  279. 279.
    Roncoroni AJ, Gomez MA, Mera J, et al. Cryptosporidium infection in renal transplant patients. J Infect Dis. 1989;160:559.CrossRefPubMedGoogle Scholar
  280. 280.
    Ditrich O, Palkovic L, Sterba J, et al. The first finding of Cryptosporidium baileyi in man. Parasitol Res. 1991;77:44–7.CrossRefPubMedGoogle Scholar
  281. 281.
    Udgiri N, Minz M, Kashyap R, et al. Intestinal cryptosporidiosis in living related transplant recipients. Transplant Proc. 2004;36:2128–9.CrossRefPubMedGoogle Scholar
  282. 282.
    Bonatti H, Barroso 2nd LF, Sawyer RG, Kotton CN, Sifri CD. Cryptosporidium enteritis in solid organ transplant recipients: multicenter retrospective evaluation of 10 cases reveals an association with elevated tacrolimus concentrations. Transpl Infect Dis. 2012;14(6):635–48.CrossRefPubMedGoogle Scholar
  283. 283.
    Campos M, Jouzdani E, Sempoux C, et al. Sclerosing cholangitis associated to cryptosporidiosis in liver transplanted children. Eur J Pediatr. 2000;159:113–5.CrossRefPubMedGoogle Scholar
  284. 284.
    Gerber DA, Green M, Jaffe R, et al. Cryptosporidial infections after solid organ transplantation in children. Pediatr Transplant. 2000;4:50–5.CrossRefPubMedGoogle Scholar
  285. 285.
    Bjoro K, Schrumpf E, Bergan A, et al. Liver transplantation for endstage hepatitis C cirrhosis in a patient with primary hypogammaglobulinaemia. Scand J Infect Dis. 1998;30:520–2.CrossRefPubMedGoogle Scholar
  286. 286.
    Denkinger CM, Harigopal P, Ruiz P, Dowdy LM. Cryptosporidium parvum- associated sclerosing colangitis in a liver transplant patient. Transpl Infect Dis. 2008;10(2):133–6.CrossRefPubMedGoogle Scholar
  287. 287.
    Ziring D, Tran R, Edelstein S, et al. Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. Transplantation. 2005;79(6):702–9.CrossRefPubMedGoogle Scholar
  288. 288.
    Delis SG, Tector J, Kato T, et al. Diagnosis and treatment of Cryptosporidium infection in intestinal transplant recipients. Transplant Proc. 2002;34:951–2.CrossRefPubMedGoogle Scholar
  289. 289.
    Manivel C, Filipovich A, Snover DC. Cryptosporidiosis as a cause of diarrhea following bone marrow transplantation. Dis Colon Rectum. 1985;28:741–2.CrossRefPubMedGoogle Scholar
  290. 290.
    Blakey JL, Barnes GL, Bishop RF, et al. Infectious diarrhea in children undergoing bone-marrow transplantation. Aust N Z J Med. 1989;19:31–6.CrossRefPubMedGoogle Scholar
  291. 291.
    Gentile G, Venditti M, Micozzi A, et al. Cryptosporidiosis in patients with hematologic malignancies. Rev Infect Dis. 1991;13:842–6.CrossRefPubMedGoogle Scholar
  292. 292.
    van Kraaij MG, Dekker AW, Verdonck LF, et al. Infectious gastroenteritis: an uncommon cause of diarrhea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant. 2000;26:299–303.CrossRefPubMedGoogle Scholar
  293. 293.
    Kang G, Srivastava A, Pulimood AB, et al. Etiology of diarrhea in patients undergoing allogeneic bone marrow transplantation in South India. Transplantation. 2002;73:1247–51.CrossRefPubMedGoogle Scholar
  294. 294.
    Müller C, Zeiser R, Grülich C, et al. Intestinal cryptosporidiosis mimicking acute graft-versus-host disease following matched unrelated hematopoietic stem cell transplantation. Transplantation. 2004;77(9):1478–9.CrossRefPubMedGoogle Scholar
  295. 295.
    Legrand F, Grenouillet F, Larosa F, et al. Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study. Bone Marrow Transplant. 2011;46(6):858–62.CrossRefPubMedGoogle Scholar
  296. 296.
    Abdo A, Klassen J, Urbanski S, Raber E, Swain MG. Reversible sclerosing colangitis secondary to cryptosporidiosis in a renal transplant patient. J Hepatol. 2003;38:688–91.CrossRefPubMedGoogle Scholar
  297. 297.
    Checkley W, White Jr AC, Jaganath D, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15(1):85–94.CrossRefPubMedGoogle Scholar
  298. 298.
    Van Lint P, Rossen JW, Vermeiren S, et al. Detection of Giardia lamblia, Cryptosporidium spp. and Entamoeba histolytica in clinical stool samples by using multiplex real-time PCR after automated DNA isolation. Acta Clin Belg. 2013;68(3):188–92.CrossRefPubMedGoogle Scholar
  299. 299.
    Bandin F, Kwon T, Linas MD, et al. Cryptosporidiosis in paediatric renal transplantation. Pediatr Nephrol. 2009;24:2245–55.CrossRefPubMedGoogle Scholar
  300. 300.
    Minz M, Udgiri NK, Heer MK, et al. Cryptosporidiasis in live related renal transplant recipients: a single center experience. Transplantation. 2004;77:1916–7.CrossRefPubMedGoogle Scholar
  301. 301.
    Faraci M, Cappelli B, Morreale G, et al. Nitazoxanide or CD3+/CD4+ lymphocytes for recovery from severe Cryptosporidium infection after allogeneic bone marrow transplant? Pediatr Transplant. 2007;11(1):113–6.CrossRefPubMedGoogle Scholar
  302. 302.
    Guidelines for preventing opportunistic infections among HIV-infected persons 2002. MMWR Morb Mortal Wkly Rep. 2002;51:1–46.Google Scholar
  303. 303.
    Didier ES, Weiss LM. Microsporidiosis: current status. Curr Opin Infect Dis. 2006;19(5):485–92.PubMedCentralCrossRefPubMedGoogle Scholar
  304. 304.
    Hocevar SN, Paddock CD, Spak CW, et al. Microsporidia Transplant Transmission Investigation Team. Microsporidiosis acquired through solid organ transplantation: a public health investigation. Ann Intern Med. 2014;160(4):213–20.PubMedCentralCrossRefPubMedGoogle Scholar
  305. 305.
    Leder K, Weller PF. Microsporidiosis. In: UpToDate, Ryan ET, (Ed), Waltham, MA. Accessed 23 May 2015.Google Scholar
  306. 306.
    Watts MR, Chan RC, Cheong EY, et al. Anncaliia algerae microsporidial myositis. Emerg Infect Dis. 2014;20(2):185–91.PubMedCentralCrossRefPubMedGoogle Scholar
  307. 307.
    Field AS, Paik JY, Stark D, et al. Myositis due to the microsporidian Anncaliia (Brachiola) algerae in a lung transplant recipient. Transpl Infect Dis. 2012;14(2):169–76.CrossRefPubMedGoogle Scholar
  308. 308.
    Bednarska M, Bajer A, Welc-Faleciak R, et al. The first case of Enterocytozoon bieneusi infection in Poland. Ann Agric Environ Med. 2013;20(2):287–8.PubMedGoogle Scholar
  309. 309.
    Rabodonirina M, Cotte L, Radenne S, Besada E, Trepo C. Microsporidiosis and transplantation. A retrospective study of 23 cases. J Eukaryot Microbiol. 2003;50(Suppl):583.Google Scholar
  310. 310.
    Sax PE, Rich JD, Pieciak WS, et al. Intestinal microsporidiosis occurring in a liver transplant recipient. Transplantation. 1995;60:617–8.CrossRefPubMedGoogle Scholar
  311. 311.
    Rabodonirina M, Bertocchi M, Desportes-Livage I, et al. Enterocytozoon bieneusi as a cause of chronic diarrhea in a heart–lung transplant recipient who was seronegative for human immunodeficiency virus. Clin Infect Dis. 1996;23:114–7.CrossRefPubMedGoogle Scholar
  312. 312.
    Gumbo T, Hobbs RE, Carlyn C, et al. Microsporidia infection in transplant patients. Transplantation. 1999;67:482–4.CrossRefPubMedGoogle Scholar
  313. 313.
    Guerard A, Rabodonirina M, Cotte L, et al. Intestinal microsporidiosis occurring in two renal transplant recipients treated with mycophenolate mofetil. Transplantation. 1999;68:699–707.CrossRefPubMedGoogle Scholar
  314. 314.
    Metge S, Van Nhieu JT, Dahmane D, et al. A case of Enterocytozoon bieneusi infection in an HIV-negative renal transplant recipient. Eur J Clin Microbiol Infect Dis. 2000;19:221–3.CrossRefPubMedGoogle Scholar
  315. 315.
    Goetz M, Eichenlaub S, Pape GR, et al. Chronic diarrhea as a result of intestinal microsporidiosis in a liver transplant recipient. Transplantation. 2001;71:334–7.CrossRefPubMedGoogle Scholar
  316. 316.
    Sing A, Tybus K, Heesemann J, et al. Molecular diagnosis of an Enterocytozoon bieneusi human genotype C infection in a moderately immunosuppressed human immunodeficiency virus seronegative liver-transplant recipient with severe chronic diarrhea. J Clin Microbiol. 2001;39:2371–2.PubMedCentralCrossRefPubMedGoogle Scholar
  317. 317.
    Lanternier F, Boutboul D, Menotti J, et al. Microsporidiosis in solid organ transplant recipients: two Enterocytozoon bieneusi cases and review. Transpl Infect Dis. 2009;11(1):83–8.CrossRefPubMedGoogle Scholar
  318. 318.
    Latib MA, Pascoe MD, Duffield MS, et al. Microsporidiosis in the graft of a renal transplant recipient. Transpl Int. 2001;14:274–7.CrossRefPubMedGoogle Scholar
  319. 319.
    Kelkar R, Sastry PS, Kulkarni SS, et al. Pulmonary microsporidial infection in a patient with CML undergoing allogeneic marrow transplant. Bone Marrow Transplant. 1997;19:179–82.CrossRefPubMedGoogle Scholar
  320. 320.
    Teachey DT, Russo P, Orenstein JM, et al. Pulmonary infection with microsporidia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;33(3):99–302.CrossRefGoogle Scholar
  321. 321.
    Nagpal A, Pritt BS, Lorenz EC, et al. Disseminated microsporidiosis in a renal transplant recipient: case report and review of the literature. Transpl Infect Dis. 2013;15(5):526–32.PubMedGoogle Scholar
  322. 322.
    Gamboa-Dominguez A, De Anda J, Donis J, Ruiz-Maza F, Visvesvara GS, Diliz H. Disseminated Encephalitozoon cuniculi infection in a Mexican kidney transplant recipient. Transplantation. 2003;75(11):1898–900.CrossRefPubMedGoogle Scholar
  323. 323.
    Levine DJ, Riley DJ, Jorgensen JH, et al. Key diagnostic features of granulomatous interstitial nephritis due to Encephalitozoon cuniculi in a lung transplant recipient. Am J Surg Pathol. 2013;37(3):447–52.CrossRefPubMedGoogle Scholar
  324. 324.
    Carlson JR, Li L, Helton CL, et al. Disseminated microsporidiosis in a pancreas/kidney transplant recipient. Arch Pathol Lab Med. 2004;128(3):e41–3.PubMedGoogle Scholar
  325. 325.
    Meissner EG, Bennett JE, Qvarnstrom Y, et al. Disseminated microsporidiosis in an immunosuppressed patient. Emerg Infect Dis. 2012;18(7):1155–8.PubMedCentralCrossRefPubMedGoogle Scholar
  326. 326.
    Anane S, Attouchi H. Microsporidiosis: epidemiology, clinical data and therapy. Gastroenterol Clin Biol. 2010;34:450–64.CrossRefPubMedGoogle Scholar
  327. 327.
    Champion L, Durrbach A, Lang P, et al. Fumagillin for treatment of intestinal microsporidiosis in renal transplant recipients. Am J Transplant. 2010;10(8):1925–30.CrossRefPubMedGoogle Scholar
  328. 328.
    Didier ES. Microsporidiosis. Clin Infect Dis. 1998;27:1–8.CrossRefPubMedGoogle Scholar
  329. 329.
    Hutin YJ, Somardier MN, Liguory O, et al. Risk factor for intestinal microsporidiosis in patients with human immunodeficiency virus infection: a case-control study. J Infect Dis. 1998;178:904–7.CrossRefPubMedGoogle Scholar
  330. 330.
    Watson DA, Asmuth D, Wanke CA. Environmental risk factors for acquisition of microsporidia in HIV-infected persons [Abstract 235]. In: Proceedings of the 34th Annual Meeting of the Infectious Diseases Society of America (New Orleans). Alexandria, VA: Infectious Diseases Society of America; 1996.Google Scholar
  331. 331.
    Bunnapradist S, Neri L, Wong W, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis. 2008;51:478–86.CrossRefPubMedGoogle Scholar
  332. 332.
    Palau L, Kemmerly S. First report of invasive amebiasis in an organ transplant recipient. Transplantation. 1997;64:936–7.CrossRefPubMedGoogle Scholar
  333. 333.
    Bavaro P, Di Girolamo G, Di Bartolomeo P, et al. Amebiasis after bone marrow transplantation one. Bone Marrow Transplant. 1994;13:213–4.PubMedGoogle Scholar
  334. 334.
    Yap FB, Lee BR. Erythema nodosum-like lesions in a renal transplant recipient. Arch Dermatol. 2011;147(6):735–40.CrossRefPubMedGoogle Scholar
  335. 335.
    Ajumobi AB, Daniels JA, Sostre CF, Trevino HH. Giardiasis in a hematopoietic stem cell transplant patient. Transpl Infect Dis. 2014;16(6):984–7.CrossRefPubMedGoogle Scholar
  336. 336.
    Azami M, Sharifi M, Hejazi SH, Tazhibi M. Intestinal parasitic infections in renal transplant recipients. Braz J Infect Dis. 2010;14(1):15–8.CrossRefPubMedGoogle Scholar
  337. 337.
    Bromiker R, Korman SH, Or R, et al. Severe giardiasis in two patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1989;4:701–3.PubMedGoogle Scholar
  338. 338.
    Valar C, Keltel E, Dal Prá RL, et al. Parasitic infection in renal transplant recipients. Transplant Proc. 2007;39(2):460–2.CrossRefPubMedGoogle Scholar
  339. 339.
    Arslan H, Inci EK, Azap OK, et al. Etiologic agents of diarrhea in solid organ recipients. Transpl Infect Dis. 2007;9(4):270–5.CrossRefPubMedGoogle Scholar
  340. 340.
    Weclawiak H, Ould-Mohamed A, Bournet B, et al. Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation. Am J Transplant. 2011;11(3):575–82.CrossRefPubMedGoogle Scholar
  341. 341.
    Ghosh K, Ayyaril M, Nirmala V. Acute GVHD involving the gastrointestinal tract and infestation with Blastocystis hominis in a patient with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;22:1115–7.CrossRefPubMedGoogle Scholar
  342. 342.
    Usluca S, Inceboz T, Unek T, Aksoy U. Isospora belli in a patient with liver transplantation. Turkiye Parazitol Derg. 2012;36(4):247–50.CrossRefPubMedGoogle Scholar
  343. 343.
    Atambay M, Bayraktar MR, Kayabas U, Yilmaz S, Bayindir Y. A rare diarrheic parasite in a liver transplant patient: Isospora belli. Transplant Proc. 2007;39(5):1693–5.CrossRefPubMedGoogle Scholar
  344. 344.
    Marathe A, Parikh K. Severe diarrhoea due to Cystoisospora belli in renal transplant patient on immunosuppressive drugs. Indian J Med Microbiol. 2013;31(2):185–7.PubMedGoogle Scholar
  345. 345.
    Koru O, Araz RE, Yilmaz YA, et al. Case report: Isospora belli infection in a renal transplant recipient. Turkiye Parazitol Derg. 2007;31(2):98–100.PubMedGoogle Scholar
  346. 346.
    Gruz F, Fuxman C, Errea A, et al. Isospora belli infection after isolated intestinal transplant. Transpl Infect Dis. 2010;12(1):69–72.CrossRefPubMedGoogle Scholar
  347. 347.
    Visvesvara GS, Arrowood MJ, Qvarnstrom Y, et al. Concurrent parasitic infections in a renal transplant patient. Emerg Infect Dis. 2013;19(12):2044–5.PubMedCentralCrossRefPubMedGoogle Scholar
  348. 348.
    ITB WORLD TRAVEL TRENDS REPORT 2013/2014. Available at Accessed 6 June 2015.
  349. 349.
    United Nations Population Fund. Available at Accessed 6 June 2015.
  350. 350.
    Poeppl W, Obwaller AG, Weiler M, et al. Emergence of sandflies (Phlebotominae) in Austria, a Central European country. Parasitol Res. 2013;112(12):4231–7.PubMedCentralCrossRefPubMedGoogle Scholar
  351. 351.
    Hartelt K, Pluta S, Oehme R, Kimmig P. Spread of ticks and tick-borne diseases in Germany due to global warming. Parasitol Res. 2008;103 Suppl 1:S109–16.CrossRefPubMedGoogle Scholar
  352. 352.
    Rossati A, Bargiacchi O, Kroumova V, Garavelli PL. [Vector transmitted diseases and climate changes in Europe]. Infez Med. 2014;22(3):179–92 (Italian).Google Scholar
  353. 353.
    Soverow JE, Wellenius GA, Fisman DN, Mittleman MA. Infectious disease in a warming world: how weather influenced West Nile virus in the United States (2001–2005). Environ Health Perspect. 2009;117(7):1049–52.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  1. 1.Department of Infectious DiseasesInstituto de NefrologíaCiudad Autonoma de Buenos AiresArgentina

Personalised recommendations